Imfinzi (durvalumab)

Free

Imfinzi (durvalumab) is an immunotherapy cancer treatment used for non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC), bile duct and gallbladder cancerhepatocellular carcinoma, endometrial cancerbladder cancer, and gastric and gastroesophageal junction cancers in certain patients.

Description

Imfinzi Price

Imfinzi (durvalumab) is an immunotherapy cancer treatment used for non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC), bile duct and gallbladder cancerhepatocellular carcinoma, endometrial cancerbladder cancer, and gastric and gastroesophageal junction cancers in certain patients. Imfinzi Price

Imfinzi is an immune checkpoint inhibitor that targets the PD-L1 protein on cancer cells, helping the immune system more effectively recognize and attack cancer cells. This may help increase overall survival, lower the risk of cancer spreading, and help shrink tumors, depending on the type of cancer.

Imfinzi is given as an infusion into a vein every 2, 3, or 4 weeks, depending on your condition. Other medicines may be part of your treatment plan, depending on your cancer type.

 

How does Imfinzi work?

Imfinzi works by blocking the PD-L1 protein on cancer cells, allowing your immune system to recognize and attack them. This helps slow the spread of cancer and can improve survival. Imfinzi Price

Imfinzi’s class of medicines is called checkpoint inhibitors.

Imfinzi’s mechanism of action (MOA) is as a programmed death-ligand 1 (PD-L1) blocking antibody. It binds and blocks PD-L1, so there is no interaction with PD-1 and CD80. This means that the immune response is now activated to work against the cancer cells.

Imfinzi can be used for cancers that have a protein called PD-L1 on the outside of the cancer cell. The PD-L1 protein helps the cancer cells hide from the immune system so that cancer cells can survive and multiply. When Imfinzi blocks PD-L1, it means the immune system is able to find cancers and destroy them.

Reviews

There are no reviews yet.

Be the first to review “Imfinzi (durvalumab)”

Your email address will not be published. Required fields are marked *